Navigation Links
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
Date:6/3/2008

ming of the filing of the BLA; the importance of certain secondary endpoints in the CORD I trial, including the difference between the pre- and post-treatment contracture angles and whether patients achieved at least a 50% reduction in their contracture compared to baseline; the utility of XIAFLEX in the treatment of Dupuytren's contracture, including the potential for XIAFLEX as the first-line treatment option for Dupuytren's contracture; the potential of XIAFLEX to revolutionize the treatment for Dupuytren's contracture; the benefits of XIAFLEX compared to surgery for the treatment of Dupuytren's contracture and the ability of XIAFLEX to address the medical need for a non-surgical treatment for Dupuytren's contracture earlier in the disease process; the period of time during which patients receiving XIAFLEX in the studies will be monitored; and products in development for Dupuytren's contracture, Peyronie's disease, Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease. All statements other than statements of historical facts contained in this release, including but not limited to, statements regarding future expectations, plans and prospects for the Company, statements regarding forward-looking financial information and other statements containing the words "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and similar expressions, as they relate to the Company, constitute forward-looking statements. Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 under the heading "Risk Factors", which is on
'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
3. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
8. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced the ... evaluating aldoxorubicin compared to topotecan in subjects with ... relapsed or were refractory to prior chemotherapy. Aldoxorubicin ... agent, doxorubicin. CytRx has received Orphan Drug Designation ...
(Date:9/29/2014)... et SAN DIEGO , ... Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) et ... la conclusion d,un accord de fusion définitif en ... totalité des actions ordinaires en circulation d,Ambit Biosciences ... le biais d,une offre publique d,achat qui sera ...
(Date:9/29/2014)... Calif. , Sept. 29, 2014  Bob Pack, ... driver, today called on the California Medical Association to ... Proposition 46 that the San Jose Mercury News called ... "practically everything it wants voters to believe about the ... ad attacks the Prop 46 requirement that doctors check ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... (PRWEB) September 30, 2014 AutoTex ... sporting the iconic pink ribbon in support of breast ... popular month for businesses and non-profits to “go pink” ... cause. , AutoTex PINK is a woman-owned company that ... They are committed to partnering with their customers ...
(Date:9/30/2014)... Minneapolis, MN (PRWEB) September 30, 2014 ... recognized leader in business technology and services was ... in First Call Effectiveness (FCE) in 2013. This ... devices properly the first time and for an ... longevity. For more than 20 years BEI Services ...
(Date:9/30/2014)... Julie Kuriakose, MD; Physician, ... will discuss how restaurants can become more allergy-friendly and ... restrictions at the 2014 Allergy Eats Food Allergy ... 21 in New York City. , “I’m extremely delighted ... such an engaged industry audience. As food allergies become ...
(Date:9/30/2014)... Up to 45% of the population snores ... have sleep apnea. Of these, only 10% have been ... tolerate their prescribed medical device known as CPAP (continuous ... which supports the airway during sleep. , In today’s ... and increasingly difficult to get. Snoring and sleep apnea ...
(Date:9/30/2014)... compared with placebo did not reduce hospital length of ... mortality, or the risk of death at 6 months ... ill, according to a study published in JAMA ... coincide with its presentation at the European Society of ... prevalence of low vitamin D levels has been confirmed ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 2Health News:Snoring: Robs People and Their Bed Partners of the Rest They Need to Face Daily Challenges 3Health News:High-dose vitamin D for ICU patients who are vitamin D deficient does not improve outcomes 2
... when choosing mates, study finds , MONDAY, June 29 (HealthDay ... a mate, according to a U.S. study that challenges the ... recruited 350 undergraduates for speed-dating events. In half the events, ... in one location. The roles were reversed in the other ...
... ... their perspectives on eye care and safety. , ... Minneapolis, MN (PRWEB) June 29, 2009 -- Stop squinting…proper eye care and ... displays in all their brilliance and clarity., , , The Healthcare Scoop , in recognition ...
... , Two MuGard US Patents Issued , , DALLAS, ... (OTC Bulletin Board: ACCP), announced today that its European partner, ... MuGard in Greece. This follows previous ... license from Access Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory ...
... Corporation (Nasdaq: AIRM ), the largest air medical ... a petition with the National Transportation Safety Board (NTSB) requesting ... June 29, 2008 mid-air collision accident in Flagstaff, Arizona. ... to see and avoid the other helicopter on approach to ...
... identified and described a mechanism whereby a single-base change in ... The focus in this study was on a common ... only a slightly increased risk of cancer. However, the risk ... and by almost 100% of African populations. The high ...
... particular can gene raise a man,s risk of familial, or ... disease, according to new research by scientists at the National ... to be identified that affects the risk of familial testicular ... The study appears in the July 2009 Cancer ...
Cached Medicine News:Health News:Maybe Men Aren't So Picky After All 2Health News:The Healthcare Scoop Community Says 'Eye Care' 2Health News:The Healthcare Scoop Community Says 'Eye Care' 3Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm 2Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm 3Health News:Air Methods Petitions NTSB for Reconsideration of Probable Cause Determination 2Health News:Risk of cancer 2Health News:Second gene linked to familial testicular cancer 2Health News:Second gene linked to familial testicular cancer 3
... design permits continuous irrigation through ... the Foley Catheter. 3-Way Catheters ... as well as LUBRICATH coatings, ... of models including Suggs, Emmett, ...
All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Intended for one-time use....
Used to provide bladder drainage by percutaneous placement of a balloon catheter. Supplied sterile in peel-open packages. Intended for one-time use....
Used for injection into urethral strictures, bladder neck contracture, and the bladder wall. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: